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Abstract
Background and Objective Technosphere® Insulin (TI), a human insulin powder for inhalation  (Afrezza®; MannKind Cor-
poration, Westlake Village, CA, USA), is an ultra-rapid-acting inhaled insulin indicated to improve postprandial glycemic 
control in patients with type 1 or type 2 diabetes mellitus (T1DM or T2DM). Because TI is absorbed across the alveolar 
membrane, the objective of this analysis was to characterize its pulmonary safety.
Methods Pooled data from 13 phase 2/3 clinical studies in 5505 patients with T1DM or T2DM treated with TI, Technosphere 
inhalation powder without insulin (TP; placebo), or active-comparator treatment were analyzed for incidences of respiratory 
treatment-emergent adverse events (TEAEs), changes in pulmonary function, and lung malignancies. Radiographic changes 
in the lungs were monitored in a subset of 229 patients.
Results Among 3017 patients receiving TI, the median duration of TI exposure was 168 days; median active-comparator and 
TP exposure durations were 363 and 149 days for 2198 and 290 patients, respectively. Respiratory TEAEs were comparable 
across treatments, except for a higher incidence of mild cough with TI in active-comparator studies (28.0% vs. 5.2%). Slight 
reversible declines in pulmonary function from baseline were observed for TI versus TP and active-comparator treatments, 
including in a subpopulation of patients with retrospectively identified lung dysfunction. Lung malignancies were reported 
in two patients on active TI therapy with a smoking history. No clinically significant changes from baseline were observed 
in radiographic images.
Conclusions Pulmonary safety assessment of the TI inhalation system did not identify any safety issues in individuals with 
either T1DM or T2DM.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 1-020-00958 -8) contains 
supplementary material, which is available to authorized users.
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Key Points 
Pulmonary safety of Technosphere Insulin, an ultra-
rapid-acting prandial insulin that is inhaled through the 
mouth and absorbed via the alveoli, is of clinical interest, 
and detailed safety information is reviewed here.
In this pulmonary safety analysis, data are assessed from 
13 pooled phase 2/3 clinical trials with Technosphere 
Insulin and demonstrate that respiratory treatment-emer-
gent adverse events, changes in pulmonary function from 
baseline, and rates of lung malignancies with inhaled 
Technosphere Insulin, active-comparator, and placebo 
treatment groups are similar. These data support that 
inhaled Technosphere Insulin is not associated with an 
excess of pulmonary safety events in the short term when 
compared with usual insulin therapy.
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population were separated by placebo-controlled and active-
comparator trials to allow for direct comparison between 
TI and placebo or TI and active comparators. Additionally, 
data were pooled and summarized for two inhaler types 
 (MedTone® and  Gen2®; MannKind Corporation, Westlake 
Village, CA, USA), and comparative data demonstrated that 
overall pulmonary safety profiles were similar between TI 
Gen2- and TI MedTone-treated groups. For pooled studies, 
the analysis population was the safety population, which 
was defined as all randomized patients who received one 
or more doses of study medication. Although there were 
variations in study designs between trials, patients generally 
were excluded if they had renal dysfunction, renal disease, or 
serum creatinine levels between 1.5 and 2.0 mg/dL for males 
or 1.3 and 1.8 mg/dL for females. Patients with a history 
of chronic obstructive pulmonary disease (COPD), asthma, 
or other clinically important pulmonary diseases were also 
excluded from the studies. Although the inclusion/exclusion 
criteria were designed to exclude patients diagnosed with 
asthma or COPD, subpopulations of patients with mild sub-
clinical lung dysfunction from the pooled phase 2/3 studies 
were retrospectively identified to assess the safety of TI in 
patients with underlying lung disease.
For studies evaluating pulmonary function, data were 
presented as individual studies because of differing study 
designs and treatment durations. These studies included 
MKC-TI-171 (open-label study in T1DM with 24-week 
treatment period), MKC-TI-162 and substudy MKC-TI-164 
(open-label studies in T2DM with 16-week treatment peri-
ods), and MKC-TI-175 (placebo-controlled, double-blind 
study in T2DM with 24-week treatment period).
High-resolution CT or MRI scans of the lungs were per-
formed to monitor the development of lung abnormalities in 
a population of 229 patients with T2DM from MKC-TI-010, 
a 4-year, open-label extension study designed to evaluate 
safety and tolerability of TI.
All studies were approved by appropriate independent 
ethics committees or institutional review boards and moni-
tored by independent data-safety-monitoring boards. All 
patients provided written informed consent.
2.2  Treatments and Exposure
Treatments included TI, Technosphere inhalation powder 
without insulin (TP; placebo), or active-comparator treat-
ment, which included subcutaneous insulin (e.g., insulin 
aspart, insulin lispro), oral glucose-lowering drugs, or usual 
care.
2.3  Pulmonary Safety
Primary pulmonary safety endpoints were respiratory 
TEAEs, including cough. A TEAE was defined as an AE 
1 Introduction
Insulin therapy is an important component of standard care 
of patients with diabetes mellitus (DM) and may be admin-
istered as a combination of basal (long-acting) insulin and 
prandial (mealtime, short-acting) insulin [1]. Prandial insu-
lin, traditionally self-administered via subcutaneous injec-
tion or infusion from an insulin pump, can also be delivered 
via pulmonary inhalation. The first inhaled insulin to be 
approved by the US Food and Drug Administration (FDA) 
was  EXUBERA® (insulin human [rDNA origin] inhalation 
powder; Pfizer Inc, New York, NY, USA) in 2006, although 
its use raised concerns about its possible effects on lung 
function and theoretical risk of lung malignancies [2–4]. 
EXUBERA was ultimately withdrawn from the market by 
the manufacturer [2].
In 2014,  Technosphere® Insulin (TI;  Afrezza®; Mann-
Kind Corporation, Westlake Village, CA, USA) was 
approved for the treatment of both type 1 DM (T1DM) and 
type 2 DM (T2DM) [5]. Technosphere Insulin, a dry pow-
der formulation of recombinant human insulin adsorbed 
onto Technosphere microparticles for oral inhalation, is an 
ultra-rapid-acting prandial inhaled insulin that has a faster 
onset (approximately 12 min) and shorter duration (approxi-
mately 3 h) of action than currently available subcutaneously 
injected insulins [5, 6].
Given the pulmonary administration route, it is clinically 
important to assess and understand effects of TI on pulmo-
nary safety/function. Technosphere Insulin has been inves-
tigated in numerous clinical studies in patients with T1DM 
or T2DM, affording the opportunity to assess its pulmonary 
safety profile in this combined cohort and in subpopulations 
of those patients with underlying abnormalities in lung func-
tion. The current study presents an integrated analysis of 
incidences of respiratory treatment-emergent adverse events 
(TEAEs) and lung malignancies, changes in measures of 
pulmonary function, and radiographic changes from baseline 
using serial high-resolution computed tomographic (CT) or 
magnetic resonance imaging (MRI) scans of patients over a 
treatment period of up to 4 years.
2  Methods
2.1  Studies and Study Populations
Data from all 13 controlled phase 2/3 clinical studies of TI 
for treatment of T1DM or T2DM with a planned continuous 
study-treatment exposure of > 14 days that were completed 
by 31 July 2013 were pooled for analysis (see Electronic 
Supplementary Material). Data from the pooled safety 
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(except for hypoglycemia) that worsened in severity on or 
after study day 1 and within 30 days of the last treatment 
dose. Respiratory TEAEs in the pooled studies, including 
cough, were summarized by preferred term and coded using 
the Medical Dictionary for Regulatory Activities (MedDRA) 
version 15.1.
Cough is an anticipated side effect of dry powder inha-
lation and therefore was also prespecified as an expected 
event of special interest. Cough events as TEAEs of special 
interest were monitored and reported on a separate cough 
case-report form (CRF). Information collected included 
cough frequency (single defined, intermittent, continuous), 
relationship to treatment, and absence or presence of spu-
tum production. In cases of mild cough, the event may not 
have been recorded as an AE. Events collected on cough 
CRFs were excluded from respiratory TEAEs summarized 
by preferred term.
To evaluate changes from baseline in pulmonary func-
tion for the individual studies (MKC-TI-171, MKC-
TI-162/164, and MKC-TI-175; Electronic Supplementary 
Material), formal spirometry testing was employed as pre-
viously described by Miller et al. [7]. Pulmonary endpoints 
included forced expiratory volume in 1 second  (FEV1) and 
forced vital capacity (FVC). All studies strictly adhered to 
American Thoracic Society or European Respiratory Society 
guidelines [7].
High-resolution CT or MRI lung scans were performed 
in 229 patients with T2DM (study MKC-TI-010). Of these 
patients, 206 had a baseline image and ≥ 1 subsequent 
image taken, allowing for assessment and inclusion in the 
analysis population. Images of the lungs were taken at 
baseline (visit 1) and annually thereafter over the 4-year 
treatment period. Scans were reviewed for abnormalities 
by an independent radiologist who was blinded to patient 
identity, investigator site, examination dates, sequence of 
examinations, and reason for imaging. Qualitative assess-
ment criteria included interlobular septal thickening, 
ground-glass opacities, tree-in-bud opacities, parenchymal 
abnormalities, consolidation, nodules or masses, bronchial 
abnormalities, pleural abnormalities, and pleural effusions. 
Patients found to be absent of all criteria for both lungs 
were deemed normal. Any result other than normal was 
submitted for additional review with clinical data to an 
independent board-certified radiologist and an independent 
board-certified pulmonologist. Secondary interpretations, 
based on the images and clinical data, included whether 
the patients’ images were normal; abnormal, not clini-
cally significant; or abnormal, clinically significant. Study 
investigators reviewed high-resolution CT or MRI reports 
and assessed the clinical significance of abnormalities.
2.4  Statistical Analysis
For TEAE reports, event rates were calculated by dividing 
number of events by patient exposure time. For pulmonary 
function tests, a mixed-effect model repeat-measurement 
analysis was performed to assess mean changes in  FEV1 
and FVC from baseline values. For change from baseline 
calculations, baseline values were defined as the last meas-
urements collected on or before study day 1 (date the first 
dose of study medication was administered).
3  Results
3.1  Patient Disposition and Baseline Characteristics
A total of 5505 patients were included in the overall safety 
population. Of these, 3017 received TI (413 in placebo-
controlled studies and 2604 in active-comparator studies), 
290 received TP and 2198 received active-comparator 
treatment. Patients in the three treatment cohorts had simi-
lar demographic characteristics, duration of diabetes, and 
smoking histories (Table 1).
Among 3017 patients receiving TI, 2023 (67.1%) com-
pleted treatment. More patients discontinued prematurely 
in the TI (32.9%) versus TP (20.0%) and active-compar-
ator (22.0%) cohorts, with the most common reasons for 
discontinuation being patient withdrawal of consent for 
personal reasons, lack of efficacy, and dissatisfaction with 
therapy.
3.2  Exposure to Treatment
Median (range) duration of exposure to treatment was 
168 (1–764), 149 (2–205), and 363 (0–810) days for 
patients receiving TI, TP, and active-comparator treat-
ment, respectively. The 3017 patients receiving TI 
had varying treatment exposure times (TI exposure: 
0–3 months, n = 896; > 3–6 months, n = 978; > 6–12 months, 
n = 419; > 12 months, n = 724).
3.3  Respiratory Treatment‑Emergent Adverse 
Events
The overall incidence of respiratory TEAEs occurring 
in ≥ 2% of each cohort was higher for TI (45.2%) than 
for TP (35.9%) and active-comparator (31.0%) treat-
ments. The most common respiratory TEAE summarized 
by MedDRA preferred term was cough. Cough incidence 
was similar between patients receiving TI (20.3%) and TP 
(19.7%) in placebo-controlled studies and higher for patients 
receiving TI (28.0%) versus active comparator (5.2%) in 
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active-comparator studies (Table 2). When recorded as a 
TEAE of special interest on a separate CRF, the incidence of 
patient-reported cough was also similar between TI (21.5%) 
and TP (20.3%) in placebo-controlled studies and higher for 
TI (27.0%) vs active comparator (5.1%) in active-comparator 
studies (Table 3).
Cough was most commonly described as mild, inter-
mittent, and limited to a single defined event that occurred 
within 10 min after TI inhalation. Cough was not persistent, 
as incidence was highest within the first week of TI treat-
ment and declined over the following 4–8 weeks. Cough 
was generally nonproductive and not associated with chronic 
sputum production. Treatment discontinuation due to cough 
was uncommon, occurring in a small proportion (2.8%) of 
patients receiving TI. Other respiratory TEAEs of special 
interest, such as asthma, wheezing, bronchospasm, and 
bronchial reactivity, were uncommon (incidence, < 0.5%) 
for patients receiving TI.
Upper respiratory tract infection (URTI) and nasopharyn-
gitis were the next most common respiratory TEAEs sum-
marized by preferred term (Table 2). Incidences of URTIs 
were comparable between cohorts in placebo-controlled (TI 
4.6%; TP 4.8%) and active-comparator (TI 10.2%; active 
comparator 10.9%) studies. Similarly, incidences of naso-
pharyngitis were comparable across cohorts in placebo-
controlled (TI 7.7%; TP 8.3%) and active-comparator (TI 
7.2%; active comparator 7.8%) studies.
In the pooled, controlled phase 2/3 studies, there were 
no deaths due to a primary respiratory TEAE. Respiratory 
TEAEs were noted as the cause of early discontinuation in 
4.6% of patients treated with TI, compared with 0.1% of 
patients in the active-comparator cohorts, respectively. This 
difference was predominantly driven by cough (TI 2.8%; 
active comparator 0%), followed by dyspnea (TI 0.5%; active 
comparator 0%).
3.4  Pulmonary Function
In study MKC-TI-171, there was a reduction in  FEV1 from 
baseline to week 24 in patients with T1DM. A greater over-
all reduction was seen in patients receiving TI (Gen2 inhaler 
− 0.07 L; MedTone inhaler − 0.08 L) than in patients receiv-
ing insulin aspart (− 0.03 L; Fig. 1a), with absolute differ-
ences in  FEV1 between TI and active-comparator treatment 
of − 0.04 L (Gen2 inhaler) and − 0.05 L (MedTone inhaler). 
Differences were no longer present at the 28-week follow-up 
visit (i.e., 4 weeks after TI treatment completion). Addition-
ally, there was a small decline in mean change from base-
line in FVC for patients receiving either TI or insulin aspart 
over the 24-week treatment period, with less of a decline in 
the insulin aspart cohort (Fig. 1b). These changes were not 
observed at week 28 of treatment.
In study MKC-TI-175, patients with T2DM receiving TI 
experienced greater declines in  FEV1 from baseline to week 
Table 1  Baseline characteristics of the safety population from pooled studies of Technosphere Insulin
BMI body mass index, SD standard deviation, TI Technosphere Insulin, TP Technosphere inhalation powder without insulin (placebo)
Parameter Placebo-controlled studies Active-comparator studies
TI (n = 413) TP (n = 290) TI (n = 2604) Active compar-
ator (n = 2198)
Sex, n (%)
 Male 222 (53.8) 139 (47.9) 1310 (50.3) 1123 (51.1)
 Female 191 (46.2) 151 (52.1) 1294 (49.7) 1075 (48.9)
Race, n (%)
 White 327 (79.2) 207 (71.4) 2164 (83.1) 1844 (83.9)
 Black 26 (6.3) 18 (6.2) 123 (4.7) 88 (4.0)
 Hispanic 55 (13.3) 55 (19.0) 238 (9.1) 193 (8.8)
 Asian 2 (0.5) 7 (2.4) 51 (2.0) 41 (1.9)
 Other 3 (0.7) 3 (1.0) 28 (1.1) 32 (1.5)
Age group, years, n (%)
 18–64 332 (80.4) 233 (80.3) 2304 (88.5) 1965 (89.4)
 65–74 75 (18.2) 52 (17.9) 286 (11.0) 216 (9.8)
  ≥ 75 6 (1.5) 5 (1.7) 14 (0.5) 17 (0.8)
BMI, mean (SD), kg/m2 30.8 (4.7) 31.8 (4.6) 29.2 (5.2) 29.1 (5.2)
Duration of diabetes, mean (SD), y 9.2 (5.4) 8.8 (5.0) 13.2 (9.1) 13.5 (9.0)
Past smoker, n (%) 135 (32.7) 84 (29.0) 680 (26.1) 590 (26.8)
Cigarettes per day, mean (SD) 17.6 (16.4) 18.1 (15.7) 15.5 (13.6) 16.7 (14.3)
Number of years smoked, mean (SD) 19.4 (11.9) 19.3 (12.1) 16.5 (11.9) 16.6 (11.7)
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Table 2  Respiratory TEAEs by preferred term observed in pooled studies of Technosphere Insulin
Adverse events were coded using the MedDRA (version 15.1)
MedDRA Medical Dictionary for Regulatory Activities, TEAE treatment-emergent adverse event, TI Technosphere Insulin, TP Technosphere 
inhalation powder without insulin (placebo)
TEAEs, n (%) Placebo-controlled studies Active-comparator studies
TI (n = 413) TP (n = 290) TI (n = 2604) Active compar-
ator (n = 2198)
Cough 84 (20.3) 57 (19.7) 729 (28.0) 114 (5.2)
Upper respiratory tract infection 19 (4.6) 14 (4.8) 265 (10.2) 239 (10.9)
Nasopharyngitis 32 (7.7) 24 (8.3) 188 (7.2) 172 (7.8)
Bronchitis 12 (2.9) 10 (3.4) 78 (3.0) 58 (2.6)
Oropharyngeal pain 12 (2.9) 8 (2.8) 65 (2.5) 25 (1.1)
Throat irritation 5 (1.2) 4 (1.4) 63 (2.4) 3 (0.1)
Productive cough 11 (2.7) 3 (1.0) 99 (3.8) 18 (0.8)
Sinusitis 4 (1.0) 3 (1.0) 51 (2.0) 49 (2.2)
Dyspnea 1 (0.2) 2 (0.7) 40 (1.5) 6 (0.3)
Viral respiratory infection 2 (0.5) 5 (1.7) 7 (0.3) 5 (0.2)
Table 3  Incidence and characteristics of cough as a TEAE of special interest in pooled studies of Technosphere Insulin
Only data from cough case-report forms are presented in this table. Cough events reported as adverse events are excluded
TEAE treatment-emergent adverse event, TI Technosphere Insulin, TP Technosphere inhalation powder without insulin (placebo)
a Percentages are based on the number of patients in each treatment cohort from the safety population
b Percentages are based on the total number of cough episodes in each treatment cohort. The ‘No’ category might include events that happened 
while patient was temporarily not on treatment
Placebo-controlled studies Active-comparator studies




 Patient-reported cough, n (%)a 89 (21.5) 59 (20.3) 703 (27.0) 112 (5.1)
 Total cough episodes, n 207 168 1257 131
Characteristics of cough episodes, n (percentage of cough episodes)b
 Frequency of cough
  Continuous 14 (6.8) 11 (6.5) 77 (6.1) 10 (7.6)
  Intermittent 101(48.8) 123 (73.2) 736 (58.6) 99 (75.6)
  Single defined 92 (44.4) 34 (20.2) 444 (35.3) 21 (16.0)
 Cough occurred within 10 min of drug inhalation
  Yes 156 (75.4) 139 (82.7) 969 (77.1) 16 (12.2)
  No 51 (24.6) 29 (17.3) 285 (22.7) 83 (63.4)
 Cough produced sputum
  Yes 29 (14.0) 11 (6.5) 175 (13.9) 26 (19.8)
  No 120 (58.0) 56 (33.3) 606 (48.2) 79 (60.3)
 Inciting event
  Spirometry 5 (2.4) 3 (1.8) 1 (0.1) 0
  Study drug 113 (54.6) 107 (63.7) 445 (35.4) 0
  Other 37 (17.9) 10 (6.0) 119 (9.5) 40 (30.5)
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12 (− 0.08 L) and week 24 (− 0.13 L) than patients receiv-
ing TP (− 0.04 L at week 12 and week 24; Fig. 1c), with 
a treatment difference at week 24 of − 0.09 L (95% confi-
dence interval [CI], − 0.12, − 0.05). There were also small 
declines in mean FVC from baseline to week 12 and week 
24 for both TI and TP cohorts. The FVC declines in the TI 
cohort (week 12, − 0.07 L; week 24, − 0.12 L) were greater 
than those of the TP cohort (week 12, − 0.04 L; week 24, 
− 0.03 L; Fig. 1d), with a treatment difference at week 24 
of − 0.09 L (95% CI, − 0.13, − 0.04). At week 28, 4 weeks 
after stopping treatment, mean  FEV1 and FVC values for 
patients receiving TI returned to levels similar to those of 
patients receiving TP.
Overall, a high percentage of patients across all treat-
ment cohorts in the MKC-TI-171 and MKC-TI-175 stud-
ies had a small (0–5%) decline from baseline to the last 
study measurement in  FEV1 (Fig. 2a, b) and FVC (data not 
shown). In both studies, a majority of TI-treated patients 
had observed declines in pulmonary function at time of last 
measurement. This distribution was similar at week 12 and 
week 24 of treatment.
Consistent with results observed in MKC-TI-171 and 
MKC-TI-175, differences in  FEV1 and FVC changes from 
baseline between patients with T2DM receiving either TI 
plus insulin glargine or insulin aspart plus insulin glargine in 
study MKC-TI-162 were small (differences in mean changes 
from baseline [TI cohort minus active-comparator cohort]: 
 FEV1 at week 6, − 0.07 L;  FEV1 at week 16, − 0.07 L; FVC 
















































































TI Gen2 inhaler (3.34 L)
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Fig. 1  In study MKC-TI-171 of patients with T1DM in which TI was 
administered with either the MedTone or Gen2 inhaler, changes from 
baseline in a  FEV1 and b FVC. In study MKC-TI-175 of patients with 
T2DM (safety population), changes from baseline in c  FEV1 and d 
FVC. Median baseline values are included in graph legends. FEV1 
forced expiratory volume in 1 second, FVC forced vital capacity, SE 
standard error, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes 
mellitus, TI Technosphere Insulin, TP Technosphere inhalation pow-
der without insulin (placebo)
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3.5  Pulmonary Safety in Special Populations
Among the pooled safety population, 101 patients were ret-
rospectively identified with subclinical reversible airway 
dysfunction, defined as patients with a > 12% and > 0.2 L 
improvement in  FEV1 pre- to post-bronchodilator at the 
screening visit (TI, n = 50; TP, n = 2; active comparator, 
n = 49). Among these patients, cough was the most com-
mon respiratory TEAE and was reported in 30.0% of 
patients in the TI cohort, compared with 12.2% in the TP/
active-comparator cohort. In lung function analyses, mean 
changes in  FEV1 values from baseline over 24  months 
slightly decreased over time (− 0.05 L) for the TI cohort 
and increased over time for the TP/active-comparator cohort 
(0.10 L). Similarly, the TI cohort demonstrated a greater 
decline from baseline in FVC over 24 months (− 0.16 L), 
whereas the TI/active-comparator cohort demonstrated an 
improvement from baseline (0.09 L).
Among the pooled safety population, 61 patients (TI, 
n = 38; TP, n = 2; active comparator, n = 21) were retro-
spectively identified as having subclinical fixed obstruc-
tive lung dysfunction, defined as patients aged > 40 years 
with a history of smoking and a post-bronchodilator 
 FEV1/FVC ratio of < 70%. Cough was observed in 21.5% 
of these patients receiving TI, compared with 0% of 
patients receiving TP or active-comparator treatment. Over 
24 months, mean changes in  FEV1 from baseline slightly 
decreased for patients receiving TI (− 0.11 L) and slightly 
increased for patients receiving TP or active-comparator 
treatment (0.09 L). At 24 months, the TI cohort also dem-
onstrated a decline from baseline in mean FVC (− 0.16 L), 
whereas the TP/active-comparator cohort demonstrated 
an improvement (0.13 L). In both retrospectively defined 
subpopulations, no bronchospasm AEs were reported.
3.6  Lung Malignancies
During the clinical trial program, there were two reported 
lung malignancies in 3283 patients (2747 patient-years 
of follow-up) receiving TI treatment and no cases of lung 
malignancy in 2205 patients (2169 patient-years of fol-
low-up) receiving active-comparator treatment. One case 
was a neuroendocrine tumor involving the lung, which 
was diagnosed 71 days after the last TI dose; the second 
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Fig. 2  Distribution of percentage change from baseline to last meas-
urement in  FEV1 in a study MKC-TI-171 (patients with T1DM in 
which TI was administered with either the MedTone or Gen2 inhaler) 
and b study MKC-TI-175 (patients with T2DM). FEV1 forced expira-
tory volume in 1 second, T1DM type 1 diabetes mellitus, T2DM type 
2 diabetes mellitus, TI Technosphere Insulin, TP Technosphere inha-
lation powder without insulin (placebo)
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was diagnosed 2 months after TI discontinuation. In both 
cases, the patients had a history of cigarette exposure of 
approximately 40 pack-years. Additionally, two cases of 
non–small-cell lung cancer in nonsmoking patients were 
diagnosed after completion of participation in clinical tri-
als (more than 2 years after completion of TI treatment). 
One of these tumors was later reclassified as a pulmonary 
blastoma. Longer-term follow-up of individuals receiving 
usual care was not routinely available.
3.7  High‑Resolution CT and MRI
A total of 206 (N = 229) patients in the analysis popula-
tion of study MKC-TI-010 received TI and had a baseline 
image plus one or more subsequent high-resolution CT 
or MRI image taken. At the 12-month follow-up, of 184 
patients with baseline and follow-up images taken, 70.7% 
had normal radiologic images; 28.3% had abnormal, not 
clinically significant images; and 1.1% had abnormal, 
clinically significant images. Of 137 patients with images 
considered normal at baseline, 136 had normal or abnor-
mal, not clinically significant images at the 12-month fol-
low-up; of the four patients with abnormal, clinically sig-
nificant radiologic images at baseline, one had abnormal, 
clinically significant images and three had abnormal, not 
clinically significant images at the 12-month follow-up.
Over the study course, six (2.6%) patients had local 
readings of lung nodules on high-resolution CTs. Although 
causality ultimately cannot be defined on the basis of these 
radiologic reviews, five were judged by the investigator to 
be unlikely related to TI exposure.
4  Discussion
Inhaled insulin offers numerous potential advantages over 
subcutaneously injected insulin, including faster insulin 
absorption rates, more rapid onset and offset of action, 
improved postprandial glucose control, and a lower risk of 
latent hypoglycemia [8]. Given the novel delivery system 
of inhaled insulin, pulmonary safety is of particular clini-
cal interest, and the incidence of AEs and drug effects on 
the respiratory system are important to understand.
The most common respiratory AEs associated with 
inhaled medications such as inhaled corticosteroids 
for asthma or inhaled antibiotics for airway infections 
include bronchoconstriction, dysphonia, throat irritation, 
and cough [9, 10]. In the current pooled safety analysis, 
the most common respiratory TEAE associated with TI 
was cough. Cough was generally mild and nonproduc-
tive, occurred within 10 min of inhalation, was observed 
early in the first week of treatment, and diminished over 
time, consistent with previously published studies of TI 
[11–13]. Incidence of cough was similar between TI and 
TP in placebo-controlled trials but higher for TI in active-
comparator trials, suggesting that the TI excipient is asso-
ciated with cough. As expected, cough was noted as the 
cause of early discontinuation in more patients receiving 
TI than in patients receiving active-comparator treatments, 
although this occurred in a minority of patients (2.8%) 
and discontinuation may have been affected by the open-
label design of the controlled studies. Patients who expe-
rienced a respiratory TEAE may have been more likely 
to discontinue treatment than if they were receiving com-
parator subcutaneous insulin in this open-label design, 
as TI is inhaled. The current analysis does not allow for 
assessment of potential bias. Incidences of other respira-
tory TEAEs, including asthma, wheezing, bronchospasm, 
and bronchial reactivity, were low, occurring in < 0.5% of 
patients receiving TI.
Potential concerns with inhaled medications include 
lung toxicity, inflammation, and anatomical injury result-
ing from the active drug product or the powder constit-
uents. In the high-resolution CT/MRI analysis (MKC-
TI-010), a small proportion (n = 2 [1.1%]) of patients had 
radiologic findings that were considered “abnormal, clini-
cally significant” at the time of their 12-month CT/MRI 
measurement, and one of these patients had “abnormal, 
clinically significant” CT/MRI scans before treatment 
began. Overall, the observed radiologic findings are not 
suggestive of a safety signal in patients treated with TI for 
at least 12 months. Published results from high-resolution 
CT/MRI analyses with the inhaled insulin EXUBERA also 
showed no significant changes in scans from baseline, fur-
ther indicating that insulin delivery via pulmonary inhala-
tion does not appear to substantially alter lung anatomy 
[3]. These findings support the conclusion that decreased 
pulmonary function is not related to drug-induced lung 
abnormalities or inflammation but may be attributable to 
other factors associated with deep-lung inhalation systems.
Diabetes is associated with a progressive decline in pul-
monary function that exceeds the decline observed in popu-
lations without diabetes [14]. This decline may be due to 
several factors, including overall higher body mass index 
(BMI) and chronic hyperglycemia effects, as indicated by 
higher hemoglobin A1C levels [14, 15]. The main factor 
accounting for the relationship between glycemic control 
and lung function may be the metabolic pathways related 
to hyperglycemia; however, several other mechanisms have 
been proposed that also consider BMI, including decreased 
respiratory muscle strength, impaired lung elasticity, defects 
in pulmonary surfactants, and low-grade chronic inflam-
mation [16]. In the current study, pulmonary function was 
evaluated in three individual studies: MKC-TI-171, MKC-
TI-175, and MKC-TI-162/164. These studies reported that 
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there were greater (though small) declines in mean  FEV1 
and FVC from baseline for the TI versus TP and active-
comparator cohorts. When looking at the distribution of 
percentage change from baseline, the observed changes in 
mean  FEV1 and FVC for TI-treated patients were driven by 
slight declines in pulmonary function (as demonstrated by 
a slight shift to the left in distribution in Fig. 2) among a 
high percentage of TI-treated patients and not by significant 
declines among a low percentage of TI-treated patients (i.e., 
outliers). For all trials assessed in the current study, such 
declines resolved 4 weeks after the end-of-treatment period, 
regardless of exposure duration. Lung function decline also 
occurs in healthy, aging individuals, with normal age-related 
declines in pulmonary function reported as ranging from 
0.02 to 0.05 L per year [17].
In the retrospectively defined subpopulation of patients 
with mild, subclinical lung dysfunction, cough was the 
most frequent respiratory TEAE, with an incidence similar 
to that of the overall safety population without underlying 
lung disease. These results support those from phase 1 
studies in prospectively defined populations with asthma 
and COPD in which cough was the most frequent respira-
tory TEAE [2, 18]. Although acute bronchospasm was 
observed after TI administration in five of 17 asthmatic 
patients in one of the aforementioned phase 1 studies, it 
could be prevented by pretreatment with bronchodilators 
[2]. Bronchospasm was not reported in phase 2/3 studies 
in patients with either reversible airway disease or fixed 
obstructive lung dysfunction. In the retrospective analyses 
presented here, there was a greater decline in pulmonary 
function in patients with underlying lung dysfunction 
receiving TI compared with those receiving TP or active-
comparator treatments. This is also consistent with phase 1 
studies in prospectively defined asthma and COPD popula-
tions, in which a moderate decline in pulmonary function 
was seen immediately (15–18 min) after TI inhalation [2, 
18]. However, the retrospectively defined studies presented 
here are limited by a small patient population evaluated at 
the completion of the study (month 24); therefore, addi-
tional studies are necessary to better establish the efficacy 
and safety of TI in these populations.
Chronic hyperinsulinemia has been proposed to play a 
role in the growth of non-small-cell lung cancer, with data 
suggesting that chronic stimulation of the insulin-like growth 
factor-1 signaling pathway may promote the rapid growth of 
existing neoplasms [19, 20]. This observation is supported 
by data demonstrating an overall increased risk of any malig-
nancy in the population of patients with long-standing dia-
betes. Comparisons between lung cancer incidences in the 
referenced TI clinical studies and published incidences in 
other studies or in the general diabetes population are lim-
ited by differences in demographics (age), study popula-
tions (smokers, ex-smokers, nonsmokers), and the low rate 
of population events. For example, comparative incidences 
assessed from studies involving nonsmokers in the general 
diabetes population most likely underestimated the expected 
incidence of lung malignancies in the TI population because 
ex-smokers were included in the TI studies. However, the 
overall incidence of lung malignancies in the TI study popu-
lation (0.8 cases per 1000 patient-years) was similar to that 
of the general population of patients with diabetes, both for 
smokers and for nonsmokers (incidence of 0.5–2.0 cases 
per 1000 patient-years) [21, 22]. There were four cases of 
lung malignancies reported among TI-treated patients: two 
were reported during the program in patients who were ex-
smokers with a long history of cigarette exposure, and two 
were reported ≥ 2 years after trial completion in nonsmokers. 
Similarly, in a 2-year observational follow-up study (FUSE) 
in patients previously treated with the inhaled insulin EXU-
BERA, it was reported that the increased risk of lung cancer-
related mortality in EXUBERA-treated patients including 
nonsmokers and those with a history of smoking was low 
(0.5 cases per 1000 patient-years) and was similar to the esti-
mated lung cancer mortality rate in the general population of 
patients with diabetes [4]. Additionally, most (7/8) patients 
with lung cancer-related mortality (EXUBERA group, n = 5; 
active-comparator group, n = 2) were prior smokers [4]. 
These data support the limited risk of malignancy observed 
in patients using inhaled insulins as compared with the 
general population of patients with diabetes. However, the 
relatively low total exposure and short exposure duration in 
the studies included in the current analysis support the need 
for further long-term follow-up of patients to better inform 
conclusions regarding the risk of malignancy in patients 
receiving inhaled TI treatment.
The patients included in this pooled pulmonary safety 
analysis were participants in randomized controlled trials 
that were part of the TI phase 2/3 clinical program. Ran-
domized controlled trials aim to reduce bias through strict 
inclusion and exclusion criteria; however, these criteria 
may exclude many patients typically seen in clinical care, 
including patients with multiple co-morbidities, potentially 
limiting the generalizability of the results [23]. Real-world 
studies and longer-term pharmacovigilance will be needed 
to further assess the long-term safety of TI in a more heter-
ogenous patient population to broaden the applicability of 
the results found here.
Another potential limitation of this analysis is the dura-
tion of TI exposure for each study, with a maximum time of 
TI exposure of 764 days for the pooled analysis and 4 years 
for MKC-TI-010. These relatively short exposure durations 
limit the ability to draw conclusions regarding any long-
term effects of TI treatment (beyond 4 years) on pulmonary 
safety, particularly risk of malignancy; additional long-term 
and follow-up studies will be helpful to further clarify the 
risk profile.
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5  Conclusions
This analysis of long-term TI use in clinical studies provides 
a pulmonary safety assessment of inhaled insulin using the 
Technosphere powder inhalation platform. No significant or 
persistent pulmonary safety concerns were identified across 
the 13 clinical trials included in this analysis, providing fur-
ther support for the use of TI treatment in adults with T1DM 
or T2DM.
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